• AcouSort shareholders approved a directed issue of convertible notes to Calyrex Biosystems at the extraordinary general meeting on October 22, 2026.
• The authorized convertible loan totals up to SEK 15 million, departing from shareholders' preemptive rights.
• The convertible notes carry 5% annual interest, maturing 30 months from payment; Calyrex may extend maturity by another 30 months.
• Full conversion of the convertible notes and accrued interest would increase share capital by up to SEK 630,263.10.
• Maximum dilution upon full conversion would be approximately 22.9%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AcouSort AB published the original content used to generate this news brief on October 22, 2026, and is solely responsible for the information contained therein.